First Time Loading...

Ascentage Pharma Group International
HKEX:6855

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
HKEX:6855
Watchlist
Price: 18.78 HKD 2.07% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Ascentage Pharma Group International

Wall Street analysts forecast Ascentage Pharma Group International stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Ascentage Pharma Group International is 30.38 HKD with a low forecast of 23.23 HKD and a high forecast of 37.8 HKD.

Lowest Forecast
Wall Street Target
23.23 HKD
24% Upside
Average Forecast
Wall Street Target
30.38 HKD
62% Upside
Highest Forecast
Wall Street Target
37.8 HKD
101% Upside
Lowest
Price Target
23.23 HKD
24% Upside
Average
Price Target
30.38 HKD
62% Upside
Highest
Price Target
37.8 HKD
101% Upside
Ascentage Pharma Group International Competitors:
Price Targets
KRTX
Karuna Therapeutics Inc
2% Downside
IMTX
Immatics NV
77% Upside
AMRN
Amarin Corporation PLC
21% Upside
ARQT
Arcutis Biotherapeutics Inc
130% Upside
KRTX
Karuna Therapeutics Inc
2% Downside
IMTX
Immatics NV
77% Upside
AMRN
Amarin Corporation PLC
21% Upside
ARQT
Arcutis Biotherapeutics Inc
130% Upside
PHM
Pharma Mar SA
70% Upside
BBIO
BridgeBio Pharma Inc
82% Upside
PTCT
PTC Therapeutics Inc
13% Downside
ADCT
ADC Therapeutics SA
112% Upside

Revenue
Forecast

Revenue Estimate
Ascentage Pharma Group International

For the last 6 years the compound annual growth rate for Ascentage Pharma Group International's revenue is 81%. The projected CAGR for the next 3 years is 60%.

81%
Past Growth
60%
Estimated Growth
Estimates Accuracy
-23%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ascentage Pharma Group International

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ascentage Pharma Group International

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Ascentage Pharma Group International's stock price target?
Price Target
30.38 HKD

According to Wall Street analysts, the average 1-year price target for Ascentage Pharma Group International is 30.38 HKD with a low forecast of 23.23 HKD and a high forecast of 37.8 HKD.

What is Ascentage Pharma Group International's Revenue forecast?
Projected CAGR
60%

For the last 6 years the compound annual growth rate for Ascentage Pharma Group International's revenue is 81%. The projected CAGR for the next 3 years is 60%.

ALPHA SPREAD
Join more than 134,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.